Plain-English translation of NCT06682988 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called in people with advanced ovarian cancer (or similar cancers) that no longer responds to standard platinum-based chemotherapy. The medication works by targeting a specific protein found on cancer cells and delivering a cell-killing drug directly to them. Researchers want to understand the best schedule and dose of this treatment and whether it's safe and effective for patients, including those with liver problems.
Platinum-resistant ovarian cancer is difficult to treat, and many patients need new options when standard chemotherapy stops working. This medication is designed to work differently—by targeting cancer cells more selectively—and this trial will help doctors determine the safest and most effective way to give it.
You likely qualify if…
You likely don't qualify if…
You will receive the new medication through an IV infusion at a hospital or clinic. Depending on which group you're in, you'll receive treatment either once every 3 weeks or twice per month (on two different schedules being tested). Over about 24 months, you'll have regular visits for medical check-ups, blood tests, and imaging scans to monitor how you're responding. The study involves more frequent medical assessments than typical standard care, so plan for regular clinic attendance.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States